Your browser doesn't support javascript.
loading
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos, Konstance; Moshi, Magdalena Ruth; Stringer, Danielle; Ma, Ning; Jenal, Mathias; Vreugdenburg, Thomas.
Afiliação
  • Nicolopoulos K; Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, Australia.
  • Moshi MR; Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, Australia. college.asernip@surgeons.org.
  • Stringer D; Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, Australia.
  • Ma N; Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, Australia.
  • Jenal M; Health Technology Assessment Section, Health Insurance Benefits Division, Health and Accident Insurance Directorate, Federal Office of Public Health (FOPH), Bern, Switzerland.
  • Vreugdenburg T; Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, Adelaide, Australia.
Arch Osteoporos ; 18(1): 18, 2023 01 10.
Article em En | MEDLINE | ID: mdl-36624318

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Conservadores da Densidade Óssea / Denosumab / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Systematic_reviews Idioma: En Revista: Arch Osteoporos Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Conservadores da Densidade Óssea / Denosumab / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Systematic_reviews Idioma: En Revista: Arch Osteoporos Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália